"The expanded agreement with Thermo Fisher Scientific, the world leader in cutting-edge life science, is a great opportunity for Devyser to expand its post-transplant business further and is a significant milestone for our company. Through this expanded collaboration, clinical labs, clinicians, and patients globally will have broad and fast access to our innovative IVDR-certified NGS-based solutions for the detection of graft rejection in stem cell transplant patients and monitoring donor-derived cell-free DNA in blood samples from kidney transplant patients,” says Fredrik Alpsten, Devyser CEO. 
 
"We are excited to expand the collaboration with Devyser and provide broader access to these post-transplant solutions under our transplant diagnostics One Lambda brand, further enabling our customers around the world to enhance patient surveillance, support graft longevity, and improve quality of life for transplant patients," says Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific. 
"Thermo Fisher Scientific is very well positioned to distribute these products globally and with their commercial infrastructure and resources, they can cover all markets quickly and efficiently. Devyser will continue to grow and focus on product development in the transplant field," says Theis Kipling, Devyser CCO. 
The agreement includes One Lambda™ Devyser Chimerism for early detection of graft rejection in stem cell transplanted patients and One Lambda™ Devyser Accept cfDNA, a novel test for detecting donor-derived cell-free DNA in kidney transplant patients, as well as the corresponding software solutions.   
The One Lambda Devyser transplantation products are CE-IVD certified but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details.